Conditional risk factors for atherosclerosis.
暂无分享,去创建一个
[1] I. Rosenberg,et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. , 1996, Circulation.
[2] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[3] V. Fuster,et al. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. , 2000, Circulation.
[4] Sonia S Anand,et al. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. , 2003, JAMA.
[5] A. Localio,et al. C-Reactive Protein and Coronary Artery Calcification: The Study of Inherited Risk of Coronary Atherosclerosis (SIRCA) , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[6] M. Malinow,et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. , 1998, The New England journal of medicine.
[7] R. Williams,et al. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study. , 1995, Atherosclerosis.
[8] F. Sacks,et al. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. , 1994, Archives of internal medicine.
[9] G. Utermann,et al. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. , 1987, The Journal of clinical investigation.
[10] Harry,et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. , 1993, Blood.
[11] A. Tajik,et al. Novel risk factors for atherosclerosis. , 2000, Mayo Clinic proceedings.
[12] Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. , 2001, Journal of the American College of Cardiology.
[13] J. Kastelein,et al. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. , 1998, Circulation.
[14] M. Laakso,et al. Elevated Plasma Homocysteine Level Is an Independent Predictor of Coronary Heart Disease Events in Patients with Type 2 Diabetes Mellitus , 2004, Annals of Internal Medicine.
[15] Ancel Keys. Coronary heart disease in seven countries. , 1971, The Medical journal of Australia.
[16] P. Ridker,et al. Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score , 2003, Circulation.
[17] E. Boerwinkle,et al. Relation of C-reactive protein and fibrinogen to coronary artery calcium in subjects with systemic hypertension. , 2003, The American journal of cardiology.
[18] L. Chambless,et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. , 2004, JAMA.
[19] R B D'Agostino,et al. Intermittent claudication. A risk profile from The Framingham Heart Study. , 1997, Circulation.
[20] S. Hazen,et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. , 2003, JAMA.
[21] J. Breslow,et al. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis , 1989, Nature.
[22] J. Hokanson,et al. Characterization of low‐density lipoprotein subclasses: methodologie approaches and clinical relevance , 1994, Current opinion in lipidology.
[23] Paul M. Ridker,et al. Prospective Study of C-Reactive Protein, Homocysteine, and Plasma Lipid Levels as Predictors of Sudden Cardiac Death , 2002, Circulation.
[24] Mark B Pepys,et al. C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.
[25] R. Matthews,et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.
[26] C. Kluft,et al. Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels; a randomized, diet-controlled intervention study , 2002, European Journal of Clinical Nutrition.
[27] E. Topol,et al. Prognostic value of myeloperoxidase in patients with chest pain. , 2003, The New England journal of medicine.
[28] P. Ueland,et al. Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. , 1998, Metabolism: clinical and experimental.
[29] T. Manolio. Novel risk markers and clinical practice. , 2003, The New England journal of medicine.
[30] A. Carter,et al. Association of the Platelet PlA Polymorphism of Glycoprotein IIb/IIIa and the Fibrinogen Bβ 448 Polymorphism With Myocardial Infarction and Extent of Coronary Artery Disease , 1997 .
[31] G. Starkebaum,et al. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. , 1986, The Journal of clinical investigation.
[32] K.,et al. Protein-bound homocyst(e)ine. A possible risk factor for coronary artery disease. , 1986, The Journal of clinical investigation.
[33] P. Ridker,et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. , 1998, Circulation.
[34] H. Superko. Small, dense, low-density lipoprotein and atherosclerosis , 2000, Current atherosclerosis reports.
[35] E. Wijsman,et al. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. , 1996, Journal of lipid research.
[36] L H Kuller,et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[37] M. King,et al. Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis. , 1988, American journal of human genetics.
[38] I. Rosenberg,et al. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. , 1996, Kidney international.
[39] P. Wilson,et al. 34th Bethesda Conference: Task force #1--Identification of coronary heart disease risk: is there a detection gap? , 2003, Journal of the American College of Cardiology.
[40] J. Coresh,et al. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. , 1993, Journal of lipid research.
[41] G. Dagenais,et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. , 1997, Circulation.
[42] G. Omenn,et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.
[43] C. Packard,et al. Effects of ciprofibrate on LDL metabolism in man. , 1994, Atherosclerosis.
[44] M. Blombäck,et al. GENETIC AND CULTURAL INHERITANCE OF PLASMA FIBRINOGEN CONCENTRATION , 1987, The Lancet.
[45] G. Assmann,et al. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[46] E. Edelman,et al. Increased Thrombosis After Arterial Injury in Human C-Reactive Protein–Transgenic Mice , 2003, Circulation.
[47] Smith Rc,et al. Pre-beta (or alpha 2) lipoprotein of high density in human blood. , 1971 .
[48] A. Dyer,et al. Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events , 2003 .
[49] G. Lippi,et al. Lipoprotein(a): from ancestral benefit to modern pathogen? , 2000, QJM : monthly journal of the Association of Physicians.
[50] E. Ernst. [Fibrinogen: a "new" cardiovascular risk factor]. , 1991, Wiener medizinische Wochenschrift.
[51] P. Weissberg,et al. Proliferation of human smooth muscle cells promoted by lipoprotein(a). , 1993, Science.
[52] C. Wolfe,et al. The VITATOPS (Vitamins to Prevent Stroke) Trial: Rationale and Design of an International, Large, Simple, Randomised Trial of Homocysteine-Lowering Multivitamin Therapy in Patients with Recent Transient Ischaemic Attack or Stroke , 2002, Cerebrovascular Diseases.
[53] P. Wilson,et al. LDL particle size distribution. Results from the Framingham Offspring Study. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.
[54] G. Rodgers,et al. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. , 1990, Blood.
[55] E. Boerwinkle,et al. Heritability of Coronary Artery Calcium Quantity Measured by Electron Beam Computed Tomography in Asymptomatic Adults , 2002, Circulation.
[56] H. Hobbs,et al. Lipoprotein(a): intrigues and insights. , 1999, Current opinion in lipidology.
[57] A. Clauss,et al. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .
[58] W. Terres,et al. Dietary fish oil lowers lipoprotein(a) in primary hypertriglyceridemia. , 1991, Atherosclerosis.
[59] J. Breslow,et al. Lipoprotein(a) reduction by N-acetylcysteine , 1991, The Lancet.
[60] A. Clayton,et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). , 2000, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[61] L. Rallidis,et al. Dietary alpha-linolenic acid decreases C-reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic patients. , 2003, Atherosclerosis.
[62] E. Topol,et al. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. , 1995, The New England journal of medicine.
[63] W C Willett,et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. , 1988, JAMA.
[64] Per Magne Ueland,et al. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. , 2002, JAMA.
[65] Paul M. Ridker,et al. C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003 .
[66] J. David Spence,et al. Vitamin Intervention for Stroke Prevention (VISP) Trial: Rationale and Design , 2001, Neuroepidemiology.
[67] A. Gaw. Can the clinical efficacy of the HMG CoA reductase inhibitors be explained solely by their effects on LDL-cholesterol? , 1996, Atherosclerosis.
[68] J. Mcconnell,et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. , 2001, Clinical chemistry.
[69] L. Kuller,et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. , 1996, American journal of epidemiology.
[70] Robert Detrano,et al. Combined Use of Computed Tomography Coronary Calcium Scores and C-Reactive Protein Levels in Predicting Cardiovascular Events in Nondiabetic Individuals , 2002, Circulation.
[71] R. Ross,et al. Atherosclerosis is an inflammatory disease. , 1998, American heart journal.
[72] E. Boerwinkle,et al. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[73] R. Krauss,et al. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. , 1992, Clinical chemistry.
[74] R. Krauss,et al. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. , 1996, JAMA.
[75] F. Kronenberg,et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. , 1999, Circulation.
[76] D. Wald,et al. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis , 2002, BMJ : British Medical Journal.
[77] Vilmundur Gudnason,et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.
[78] P. Wilson,et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. , 1996, JAMA.
[79] R. Krauss,et al. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. , 1992, Atherosclerosis.
[80] A. Scanu. Lipoprotein(a). A genetic risk factor for premature coronary heart disease. , 1992, JAMA.
[81] R Peto,et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. , 1998, JAMA.
[82] Philip Greenland,et al. Prevention Conference V Beyond Secondary Prevention : Identifying the High-Risk Patient for Primary Prevention : Executive Summary , 2000 .
[83] R. D'Agostino,et al. Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.
[84] N. Maeda,et al. Endothelial Dysfunction and Elevation of S-Adenosylhomocysteine in Cystathionine &bgr;-Synthase–Deficient Mice , 2001, Circulation research.
[85] Richard H. Myers,et al. Familial Lipoprotein Disorders in Patients With Premature Coronary Artery Disease , 1992, Circulation.
[86] C. Tack,et al. Troglitazone Decreases the Proportion of Small, Dense LDL and Increases the Resistance of LDL to Oxidation in Obese Subjects , 1998, Diabetes Care.
[87] L. Campeau,et al. Relation of coronary artery disease in women < 60 years of age to the combined elevation of serum lipoprotein (a) and total cholesterol to high-density cholesterol ratio. , 1993, The American journal of cardiology.
[88] Gary L Myers,et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.
[89] Johan Malm,et al. Selective thyroid hormone receptor-β activation: A strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[90] L. Mosca. C-reactive protein--to screen or not to screen? , 2002, The New England journal of medicine.
[91] N Rifai,et al. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. , 2001, Clinical chemistry.
[92] G. Di Minno,et al. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[93] J. Ordovás,et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. , 1994, JAMA.
[94] P. Ridker,et al. A prospective study of lipoprotein(a) and the risk of myocardial infarction. , 1993, JAMA.
[95] J. Després,et al. Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[96] P. Libby,et al. Novel inflammatory markers of coronary risk: theory versus practice. , 1999, Circulation.
[97] E. Boerwinkle,et al. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.
[98] I. Rosenberg,et al. The atherogenic effect of excess methionine intake , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[99] R. Tracy. Epidemiological Evidence for Inflammation in Cardiovascular Disease , 1999, Thrombosis and Haemostasis.
[100] C. Wanner,et al. Lipoprotein(a) : new insights into an atherogenic lipoprotein , 1994, The clinical investigator.
[101] M. McGovern,et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. , 2002, The American journal of cardiology.
[102] T. Rabelink,et al. Folates and Cardiovascular Disease , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[103] E. Ernst,et al. Fibrinogen as a Cardiovascular Risk Factor , 1993, Annals of Internal Medicine.
[104] S M Grundy,et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 1999, Circulation.
[105] W. Kannel,et al. Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. , 1961, Annals of internal medicine.
[106] N. Marx,et al. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. , 2004, Circulation research.
[107] R. D'Agostino,et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. , 1999, Archives of internal medicine.
[108] A. Gotto,et al. Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects. , 1996, Journal of lipid research.
[109] G. Bondjers,et al. Effect of proteoglycans on lipoprotein-cell interactions: possible contribution to atherogenesis , 1990 .
[110] C. Meisinger,et al. C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score: Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany , 2004, Circulation.
[111] P. Wilson,et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. , 1999, The New England journal of medicine.
[112] A. von Eckardstein,et al. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. , 1996, The American journal of cardiology.
[113] A. Moustapha,et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. , 1998, Circulation.
[114] P. Wilson,et al. Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. , 1999, Clinical chemistry.
[115] S. Bondurant. Symposium on Research on Acute Myocardial Infarction , 1970 .
[116] B. Asztalos,et al. Clinical significance of lipoprotein size and risk for coronary atherosclerosis. , 1995, Clinical chemistry.
[117] B. Culleton,et al. Hyperhomocysteinemia in chronic renal disease. , 1999, Journal of the American Society of Nephrology : JASN.
[118] N Rifai,et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. , 2001, JAMA.
[119] J. Cooke,et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. , 1999, Circulation.
[120] F. Lindgren,et al. Flotation rates, molecular weights and hydrated densities of the low-density lipoproteins , 1969, Lipids.
[121] S. Kihara,et al. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. , 1998, Circulation.
[122] G. Lowe,et al. Plasma fibrinogen, haemostatic factors and prediction of peripheral arterial disease in the Edinburgh Artery Study , 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[123] K. Hajjar,et al. The role of lipoprotein(a) in atherogenesis and thrombosis. , 1996, Annual review of medicine.
[124] F. Cambien,et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. , 2003, The New England journal of medicine.
[125] M. Weintraub,et al. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. , 1989, Circulation.
[126] E. Boerwinkle,et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. , 1992, The Journal of clinical investigation.
[127] R. Hammer,et al. Atherogenesis in transgenic mice expressing human apolipoprotein(a) , 1992, Nature.
[128] S. Mudd. Vascular disease and homocysteine metabolism. , 1985, The New England journal of medicine.
[129] S. Devaraj,et al. C-Reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression and Activity in Human Aortic Endothelial Cells: Implications for the Metabolic Syndrome and Atherothrombosis , 2003, Circulation.
[130] S. Grundy,et al. Effect of Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitor Therapy on High Sensitive C-Reactive Protein Levels , 2001, Circulation.
[131] J. Manson,et al. A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods. The WACS Research Group. , 1995, Annals of epidemiology.
[132] K. Bailey,et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. , 2001, The New England journal of medicine.
[133] H. Hendriks,et al. Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels , 2001 .
[134] Lawrence A Leiter,et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. , 2003, JAMA.
[135] H. Brewer,et al. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. , 1985, Atherosclerosis.
[136] Lan Li,et al. C-Reactive Protein Accelerates the Progression of Atherosclerosis in Apolipoprotein E–Deficient Mice , 2004, Circulation.
[137] W. Vermaak,et al. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. , 1993, The American journal of clinical nutrition.
[138] L. Wilhelmsen,et al. Fibrinogen as a risk factor for stroke and myocardial infarction. , 1984, The New England journal of medicine.
[139] B. Psaty,et al. Associations of Postmenopausal Estrogen Use With Cardiovascular Disease and Its Risk Factors in Older Women , 1993, Circulation.
[140] R. Schlegel,et al. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. , 1996, The Journal of clinical investigation.
[141] A. Ariyo,et al. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. , 2003, The New England journal of medicine.
[142] I. T. Ten Berge,et al. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. , 1996, Journal of immunology.
[143] A. Simon,et al. Fibrinogen and its relations to subclinical extracoronary and coronary atherosclerosis in hypercholesterolemic men. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[144] M. Lehtinen,et al. Fibrinogen: a comparison of an immunoturbidimetric method with four conventional methods. , 2008, Clinical and laboratory haematology.
[145] M. Secic,et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. , 1994, Clinical chemistry.
[146] R. Muche,et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS) , 1994, European journal of clinical investigation.
[147] R. Krauss,et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. , 1996, JAMA.
[148] R. D'Agostino,et al. Association of Fibrinogen With Cardiovascular Risk Factors and Cardiovascular Disease in the Framingham Offspring Population , 2000, Circulation.
[149] B. Gersh,et al. Markers of inflammation and thrombosis: clues to plaque instability? , 2003, American heart journal.
[150] K. Mccully. Homocystinuria, arteriosclerosis, methylmalonic aciduria, and methyltransferase deficiency: a key case revisited. , 2009, Nutrition reviews.
[151] J. Bastard,et al. Interpretation of circulating C-reactive protein levels in adults: body mass index and gender are a must. , 2003, Diabetes & metabolism.
[152] K. Pettigrew,et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. , 1985, American journal of human genetics.
[153] Petra Verhoef,et al. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. , 2002, JAMA.
[154] G. Lowe,et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.
[155] G. Rodgers,et al. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. , 1986, The Journal of clinical investigation.
[156] D. Wilcken,et al. Homocystinuria--the effects of betaine in the treatment of patients not responsive to pyridoxine. , 1983, The New England journal of medicine.
[157] M. Myerson,et al. High Levels of Lp(a) With a Small Apo(a) Isoform Are Associated With Coronary Artery Disease in African American and White Men , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[158] G. Dagenais,et al. Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). , 2002, The American journal of cardiology.
[159] C. Packard,et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. , 1994, Atherosclerosis.
[160] E. Braunwald,et al. Cardiology: the past, the present, and the future , 2003 .
[161] Paul T. Williams,et al. Smallest LDL Particles Are Most Strongly Related to Coronary Disease Progression in Men , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[162] B. G. Brown,et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). , 1995, JAMA.
[163] B. Nordestgaard,et al. Atherosclerosis and arterial influx of lipoproteins. , 1994, Current opinion in lipidology.
[164] J. Hendriks,et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.
[165] J. Witteman,et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. , 1997, JAMA.
[166] G. Mancia,et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force Of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). , 2004, Archives des maladies du coeur et des vaisseaux.
[167] Heejung Bang,et al. Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study , 2004, Circulation.
[168] E. Topol,et al. Prevalence of Conventional Risk Factors in Patients With Coronary Heart Disease , 2003 .
[169] R. Krauss,et al. Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. , 1990, Arteriosclerosis.
[170] N. Rifai,et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). , 2000, Clinical chemistry.
[171] P. Lesnik,et al. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. , 1991, Journal of lipid research.
[172] E. Ernst. The role of fibrinogen as a cardiovascular risk factor. , 1993, Atherosclerosis.
[173] D. Capuzzi,et al. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. , 1998, The American journal of cardiology.
[174] R. Krauss,et al. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. , 1982, Journal of lipid research.
[175] P. Ridker. Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial. , 2001, European heart journal.
[176] G. Lippi,et al. Testosterone-induced suppression of lipoprotein(a) in normal men; relation to basal lipoprotein(a) level. , 1996, Atherosclerosis.
[177] J. Danesh,et al. Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies , 2000, Circulation.
[178] Ren-Ke Li,et al. A Self-Fulfilling Prophecy: C-Reactive Protein Attenuates Nitric Oxide Production and Inhibits Angiogenesis , 2002, Circulation.
[179] A. Scanu. Structural and functional polymorphism of lipoprotein(a): biological and clinical implications. , 1995, Clinical chemistry.
[180] Aldons J. Lusis,et al. Atherosclerosis : Vascular biology , 2000 .
[181] E. Ernst. Lowering the plasma fibrinogen concentration with drugs. , 1992, Clinical pharmacy.
[182] Philip Greenland,et al. Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations , 1999 .
[183] C. Sobey,et al. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. , 1996, The Journal of clinical investigation.
[184] S. Lord,et al. A Novel Transgenic Mouse Model of Hyperfibrinogenemia , 2001, Thrombosis and Haemostasis.
[185] E. Ernst,et al. Abstention from chronic cigarette smoking normalizes blood rheology. , 1987, Atherosclerosis.
[186] P. Durand,et al. Acute methionine load‐induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage‐derived tissue factor activity in rats , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[187] E. Vittinghoff,et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. , 2000, Journal of the American Medical Association (JAMA).